Research programme: anticancer monoclonal antibodies - Nybo Therapeutics
Alternative Names: NYB 101Latest Information Update: 28 May 2021
At a glance
- Originator Nybo Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 11 Apr 2017 Preclinical trials in Solid tumours in USA (Parenteral)
- 11 Apr 2017 PureTech in-licenses immuno-oncology technology related to inhibition of gamma delta cells from New York University School of Medicine